HER2 Support Group Forums

HER2 Support Group Forums (https://her2support.org/vbulletin/index.php)
-   her2group (https://her2support.org/vbulletin/forumdisplay.php?f=28)
-   -   Phase II trial of PD0332991 (https://her2support.org/vbulletin/showthread.php?t=59304)

Redwolf8812 10-15-2013 08:33 AM
Phase II trial of PD0332991
 
I'm currently being screened for this study. May God's will be done and I pray for the Grace to accept His Will for me. Will keep you updated.

- Penny

'lizbeth 10-15-2013 10:54 AM
Re: Phase II trial of PD0332991
 
Penny,

I had to check it out online. We are seeing many new possibilities pop up for clinical trials. I'm praying that the Lord will watch over you while you wait for news about enrolling in this study.

Thank you for consider a clinical trial. And, of course, we will be waiting to hear if you are able to join.

NCT01740427

Palbociclib

A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer



Is it with Letrozole?

StephN 10-15-2013 03:23 PM
Re: Phase II trial of PD0332991
 
Penny -
Is that the right clinical trial?

I see you are hormone neg/neg in your signature, so am wondering why your onc would have you try for a study with Letrozole, which I thought was a kind of hormone suppressor? And First Line.

Redwolf8812 10-15-2013 04:06 PM
Re: Phase II trial of PD0332991
 
No that's the wrong one. The one I'm being screened for is getting ready to close and I couldn't find it online myself. I'd be getting the inhibitor with herceptin. I believe hormone factor is not an issue. If I find something online I'll post it. Thanks.

KDR 10-15-2013 04:43 PM
Re: Phase II trial of PD0332991
 
That's exactly what I'm doing after surgery, an AI and Herceptin. Getting CEA done every three weeks. Currently remain NED. Will test again Friday. I HATE doing this.


Karen

'lizbeth 10-16-2013 11:05 AM
Re: Phase II trial of PD0332991
 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790859/

I see Dennis Slamon listed on this publication. He mentioned working with ER positive cancers.

Lani just posted about DCIS and the CDK4/6

Quote:
The processes that control the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer remain poorly understood. Epidermal growth factor receptor 2 (ErbB2) overexpression is common in DCIS, as is disruption of the retinoblastoma tumor suppressor (RB) pathway. Here, we examined the cooperative impact of ErbB2 and RB deregulation on facets of disease progression. Our studies demonstrate that RB deficiency altered the expression of key molecules needed for proper cellular organization and epithelial cell-cell adhesion as part of a program related to the epithelial-to-mesenchymal transition (EMT). An increase in the invasive potential of ErbB2-overexpressing cells was observed upon RB depletion. Further, stable knockdown of RB resulted in invasive lesions in orthotopic xenograft assays, compared with DCIS-like lesions developing from RB-proficient cells. Conversely, the invasive phenotype observed in ErbB2-positive cancer models was inhibited through CDK4/6 inhibition in an RB-dependent manner. Finally, in a cohort of DCIS cases, we show that, although elevated levels of ErbB2 are associated with increased risk of a subsequent DCIS recurrence, it is not associated with progression to invasive disease. In contrast, RB loss in ErbB2-positive DCIS cases was associated with increased risk for invasive breast cancer. Taken together, these data demonstrate a key role for the RB pathway in invasion associated with breast tumor progression, and shed light on the key molecular events that promote the progression of DCIS to invasive disease.
So, you ladies are considering a trial for ER negative, Her2 positive? I'm going to search for more information on that trial.


All times are GMT -7. The time now is 08:54 PM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2025, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021